Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia

Somaia Mohamed, Robert Rosenheck, Ilan Harpaz-Rotem, Douglas Leslie, Michael J. Sernyak

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Although long-acting injectable risperidone (LAIR) has been hypothesized to improve medication adherence compared to oral medications, data from real-world practice have yet to be presented on time to treatment discontinuation. Records of all new prescriptions for antipsychotic medication during the first 2 months of FY 2006 for VA patients diagnosed with schizophrenia (N = 11,821) were examined and duration of treatment with LAIR and oral antipsychotics were calculated for the next 2 years. Multivariable logistic regression was used to identify patient characteristics independently associated with receipt of LAIR. Proportional hazards models were used to compare the likelihood of discontinuing each of the medications as compared to LAIR. Altogether, 2.4% of the 11,821 new starts were prescribed LAIR, 44.6% of whom continued therapy for 540-720 days (18-24 months), less than the 77.1% of those on clozapine, 57.9% on oral conventional antipsychotics, 55.0% on olanzapine, and 49.5% on risperidone, but more than the 27.7% on aripiprazole. After adjusting for potentially confounding factors, patients who were initiated on LAIR were more likely to discontinue their medication than those who were initiated on oral first- or second-generation antipsychotics (SGAs) with the exception ziprasidone and aripiprazole. Less than half of patients on LAIR continued treatment for 18 months, a smaller proportion than of those started on most oral first- or second-generation antipsychotics, suggesting that for many patients with schizophrenia improved adherence from this treatment may not be sustained.

Original languageEnglish (US)
Pages (from-to)241-249
Number of pages9
JournalPsychiatric Quarterly
Volume80
Issue number4
DOIs
StatePublished - Dec 1 2009

Fingerprint

Risperidone
Schizophrenia
Drug Therapy
Injections
Antipsychotic Agents
Therapeutics
olanzapine
Medication Adherence
Clozapine
Proportional Hazards Models
Prescriptions
Logistic Models

All Science Journal Classification (ASJC) codes

  • Psychiatry and Mental health

Cite this

Mohamed, Somaia ; Rosenheck, Robert ; Harpaz-Rotem, Ilan ; Leslie, Douglas ; Sernyak, Michael J. / Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. In: Psychiatric Quarterly. 2009 ; Vol. 80, No. 4. pp. 241-249.
@article{640eeca546c44fb18761ae101fb92eca,
title = "Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia",
abstract = "Although long-acting injectable risperidone (LAIR) has been hypothesized to improve medication adherence compared to oral medications, data from real-world practice have yet to be presented on time to treatment discontinuation. Records of all new prescriptions for antipsychotic medication during the first 2 months of FY 2006 for VA patients diagnosed with schizophrenia (N = 11,821) were examined and duration of treatment with LAIR and oral antipsychotics were calculated for the next 2 years. Multivariable logistic regression was used to identify patient characteristics independently associated with receipt of LAIR. Proportional hazards models were used to compare the likelihood of discontinuing each of the medications as compared to LAIR. Altogether, 2.4{\%} of the 11,821 new starts were prescribed LAIR, 44.6{\%} of whom continued therapy for 540-720 days (18-24 months), less than the 77.1{\%} of those on clozapine, 57.9{\%} on oral conventional antipsychotics, 55.0{\%} on olanzapine, and 49.5{\%} on risperidone, but more than the 27.7{\%} on aripiprazole. After adjusting for potentially confounding factors, patients who were initiated on LAIR were more likely to discontinue their medication than those who were initiated on oral first- or second-generation antipsychotics (SGAs) with the exception ziprasidone and aripiprazole. Less than half of patients on LAIR continued treatment for 18 months, a smaller proportion than of those started on most oral first- or second-generation antipsychotics, suggesting that for many patients with schizophrenia improved adherence from this treatment may not be sustained.",
author = "Somaia Mohamed and Robert Rosenheck and Ilan Harpaz-Rotem and Douglas Leslie and Sernyak, {Michael J.}",
year = "2009",
month = "12",
day = "1",
doi = "10.1007/s11126-009-9111-9",
language = "English (US)",
volume = "80",
pages = "241--249",
journal = "Psychiatric Quarterly",
issn = "0033-2720",
publisher = "Kluwer Academic/Human Sciences Press Inc.",
number = "4",

}

Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia. / Mohamed, Somaia; Rosenheck, Robert; Harpaz-Rotem, Ilan; Leslie, Douglas; Sernyak, Michael J.

In: Psychiatric Quarterly, Vol. 80, No. 4, 01.12.2009, p. 241-249.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia

AU - Mohamed, Somaia

AU - Rosenheck, Robert

AU - Harpaz-Rotem, Ilan

AU - Leslie, Douglas

AU - Sernyak, Michael J.

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Although long-acting injectable risperidone (LAIR) has been hypothesized to improve medication adherence compared to oral medications, data from real-world practice have yet to be presented on time to treatment discontinuation. Records of all new prescriptions for antipsychotic medication during the first 2 months of FY 2006 for VA patients diagnosed with schizophrenia (N = 11,821) were examined and duration of treatment with LAIR and oral antipsychotics were calculated for the next 2 years. Multivariable logistic regression was used to identify patient characteristics independently associated with receipt of LAIR. Proportional hazards models were used to compare the likelihood of discontinuing each of the medications as compared to LAIR. Altogether, 2.4% of the 11,821 new starts were prescribed LAIR, 44.6% of whom continued therapy for 540-720 days (18-24 months), less than the 77.1% of those on clozapine, 57.9% on oral conventional antipsychotics, 55.0% on olanzapine, and 49.5% on risperidone, but more than the 27.7% on aripiprazole. After adjusting for potentially confounding factors, patients who were initiated on LAIR were more likely to discontinue their medication than those who were initiated on oral first- or second-generation antipsychotics (SGAs) with the exception ziprasidone and aripiprazole. Less than half of patients on LAIR continued treatment for 18 months, a smaller proportion than of those started on most oral first- or second-generation antipsychotics, suggesting that for many patients with schizophrenia improved adherence from this treatment may not be sustained.

AB - Although long-acting injectable risperidone (LAIR) has been hypothesized to improve medication adherence compared to oral medications, data from real-world practice have yet to be presented on time to treatment discontinuation. Records of all new prescriptions for antipsychotic medication during the first 2 months of FY 2006 for VA patients diagnosed with schizophrenia (N = 11,821) were examined and duration of treatment with LAIR and oral antipsychotics were calculated for the next 2 years. Multivariable logistic regression was used to identify patient characteristics independently associated with receipt of LAIR. Proportional hazards models were used to compare the likelihood of discontinuing each of the medications as compared to LAIR. Altogether, 2.4% of the 11,821 new starts were prescribed LAIR, 44.6% of whom continued therapy for 540-720 days (18-24 months), less than the 77.1% of those on clozapine, 57.9% on oral conventional antipsychotics, 55.0% on olanzapine, and 49.5% on risperidone, but more than the 27.7% on aripiprazole. After adjusting for potentially confounding factors, patients who were initiated on LAIR were more likely to discontinue their medication than those who were initiated on oral first- or second-generation antipsychotics (SGAs) with the exception ziprasidone and aripiprazole. Less than half of patients on LAIR continued treatment for 18 months, a smaller proportion than of those started on most oral first- or second-generation antipsychotics, suggesting that for many patients with schizophrenia improved adherence from this treatment may not be sustained.

UR - http://www.scopus.com/inward/record.url?scp=71449109074&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=71449109074&partnerID=8YFLogxK

U2 - 10.1007/s11126-009-9111-9

DO - 10.1007/s11126-009-9111-9

M3 - Article

VL - 80

SP - 241

EP - 249

JO - Psychiatric Quarterly

JF - Psychiatric Quarterly

SN - 0033-2720

IS - 4

ER -